Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections

REFERENCES 1 Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349–355. 2 Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011; 37: 384–392. 3 Krüger S, Ewig S, Kunde J, et al. Assessment of inflammatory markers in patients with community-acquired pneumonia: influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010; 411: 1929–1934. 4 Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 48–58. 5 Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 2006; 10: R96. 6 Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823–831. 7 Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict shortand long-term survival in communityacquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182: 1426–1434.